Raymond James analyst Michael Freeman upgraded NervGen Pharma (NGENF) to Outperform from Market Perform with a price target of C$4.50, up from C$3.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio